Cytokine Storm Analysis Agent
The Cytokine Storm Analysis Agent provides comprehensive AI-driven analysis of cytokine release syndrome (CRS) and hyperinflammatory states. It integrates cytokine profiling, clinical parameters, and immunological markers for early prediction, severity grading, and treatment guidance in CAR-T therapy, sepsis, and viral infections.
When to Use This Skill
- When monitoring CAR-T patients for cytokine release syndrome risk.
- To predict CRS severity and timing post-immunotherapy.
- For analyzing cytokine panels in sepsis and viral infections (COVID-19).
- When guiding tocilizumab/siltuximab anti-IL-6 therapy decisions.
- To distinguish CRS from ICANS, HLH, and other inflammatory syndromes.
Core Capabilities
CRS Risk Prediction: ML models predict CRS development and severity from baseline factors (tumor burden, disease type, CAR-T product).
Real-Time Monitoring: Track cytokine dynamics (IL-6, IFN-γ, IL-10, ferritin) with early warning alerts.
Severity Grading: Automated ASTCT CRS grading using clinical parameters and biomarkers.
Differential Diagnosis: Distinguish CRS from HLH/MAS, ICANS, infection, and tumor lysis syndrome.
Treatment Guidance: AI-driven recommendations for tocilizumab, corticosteroids, and supportive care.
Outcome Prediction: Model response to anti-cytokine therapy and overall outcomes.
Cytokine Panel Analysis
| Cytokine |
Role in CRS |
Kinetics |
Therapeutic Target |
| IL-6 |
Central mediator |
Early peak |
Tocilizumab, Siltuximab |
| IFN-γ |
T-cell activation |
Early |
Emapalumab |
| IL-1β |
Inflammasome |
Early |
Anakinra |
| IL-10 |
Regulatory |
Variable |
- |
| TNF-α |
Pro-inflammatory |
Early |
Infliximab (caution) |
| IL-2 |
T-cell expansion |
Early |
- |
| GM-CSF |
Myeloid activation |
Sustained |
Lenzilumab |
ASTCT CRS Grading (Automated)
| Grade |
Fever |
Hypotension |
Hypoxia |
| 1 |
≥38°C |
None |
None |
| 2 |
≥38°C |
Responsive to fluids |
Low-flow O2 |
| 3 |
≥38°C |
One vasopressor |
High-flow O2 |
| 4 |
≥38°C |
Multiple vasopressors |
Ventilation |
Workflow
Input: Cytokine levels, vital signs, laboratory values, treatment history.
Risk Assessment: Baseline CRS risk stratification pre-therapy.
Monitoring: Real-time cytokine tracking with trend analysis.
Grading: Automated CRS grade assignment per ASTCT criteria.
Differential: Rule out mimics (infection, HLH, ICANS).
Treatment: Generate management recommendations.
Output: CRS risk score, grade, differential diagnosis, treatment plan.
Example Usage
User: "Monitor this CAR-T patient's cytokine levels and predict CRS severity."
Agent Action:
python3 Skills/Immunology_Vaccines/Cytokine_Storm_Analysis_Agent/crs_analyzer.py \
--patient_data demographics.json \
--cytokines cytokine_panel.csv \
--vitals vital_signs.csv \
--labs laboratory_values.csv \
--cart_product tisagenlecleucel \
--day_post_infusion 5 \
--model crs_predictor_v3 \
--output crs_report.json
AI/ML Models
CRS Risk Prediction:
- Features: tumor burden (LDH), lymphodepletion intensity, CAR-T dose, disease type
- Model: Gradient boosting with SHAP interpretability
- Performance: AUC 0.82-0.88 for severe CRS
Severity Trajectory:
- Time-series modeling of cytokine dynamics
- LSTM networks for temporal patterns
- Early warning 24-48 hours before clinical deterioration
Treatment Response:
- Tocilizumab response prediction
- Corticosteroid escalation timing
- ICU admission risk
Differential Diagnosis Decision Tree
Fever + Elevated Cytokines
|
CAR-T context?
/ \
Yes No
| |
Hypotension? Infection workup
| |
CRS Sepsis vs viral
|
Neuro symptoms?
|
ICANS vs CRS
|
Ferritin >10,000?
|
HLH/MAS evaluation
Clinical Decision Support
Tocilizumab Indication:
- Grade 2+ CRS
- Rapidly rising cytokines
- High-risk baseline features
Corticosteroid Indication:
- Tocilizumab-refractory CRS
- ICANS any grade
- Grade 3+ CRS
Prerequisites
- Python 3.10+
- scikit-learn, XGBoost for ML
- Time-series analysis libraries
- FHIR client for EHR integration
Related Skills
- CART_Design_Optimizer_Agent - For CAR-T design
- TCell_Exhaustion_Analysis_Agent - For T-cell function
- Clinical_NLP - For extracting symptoms from notes
Special Populations
- Pediatric: Different baseline cytokine ranges
- Post-COVID: Altered inflammatory responses
- Bridging Therapy: Impact on CRS risk
- Concurrent Infection: Confounding cytokine elevation
Author
AI Group - Biomedical AI Platform
1---2name: cytokine-storm-analysis-agent3description: AI-powered cytokine release syndrome (CRS) and cytokine storm analysis for prediction, monitoring, and management in immunotherapy and infectious disease.4---56<!--7# COPYRIGHT NOTICE8# This file is part of the "Universal Biomedical Skills" project.9# Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>10# All Rights Reserved.11#12# This code is proprietary and confidential.13# Unauthorized copying of this file, via any medium is strictly prohibited.14#15# Provenance: Authenticated by MD BABU MIA1617-->18192021# Cytokine Storm Analysis Agent2223The **Cytokine Storm Analysis Agent** provides comprehensive AI-driven analysis of cytokine release syndrome (CRS) and hyperinflammatory states. It integrates cytokine profiling, clinical parameters, and immunological markers for early prediction, severity grading, and treatment guidance in CAR-T therapy, sepsis, and viral infections.2425## When to Use This Skill2627* When monitoring CAR-T patients for cytokine release syndrome risk.28* To predict CRS severity and timing post-immunotherapy.29* For analyzing cytokine panels in sepsis and viral infections (COVID-19).30* When guiding tocilizumab/siltuximab anti-IL-6 therapy decisions.31* To distinguish CRS from ICANS, HLH, and other inflammatory syndromes.3233## Core Capabilities34351. **CRS Risk Prediction**: ML models predict CRS development and severity from baseline factors (tumor burden, disease type, CAR-T product).36372. **Real-Time Monitoring**: Track cytokine dynamics (IL-6, IFN-γ, IL-10, ferritin) with early warning alerts.38393. **Severity Grading**: Automated ASTCT CRS grading using clinical parameters and biomarkers.40414. **Differential Diagnosis**: Distinguish CRS from HLH/MAS, ICANS, infection, and tumor lysis syndrome.42435. **Treatment Guidance**: AI-driven recommendations for tocilizumab, corticosteroids, and supportive care.44456. **Outcome Prediction**: Model response to anti-cytokine therapy and overall outcomes.4647## Cytokine Panel Analysis4849| Cytokine | Role in CRS | Kinetics | Therapeutic Target |50|----------|-------------|----------|-------------------|51| IL-6 | Central mediator | Early peak | Tocilizumab, Siltuximab |52| IFN-γ | T-cell activation | Early | Emapalumab |53| IL-1β | Inflammasome | Early | Anakinra |54| IL-10 | Regulatory | Variable | - |55| TNF-α | Pro-inflammatory | Early | Infliximab (caution) |56| IL-2 | T-cell expansion | Early | - |57| GM-CSF | Myeloid activation | Sustained | Lenzilumab |5859## ASTCT CRS Grading (Automated)6061| Grade | Fever | Hypotension | Hypoxia |62|-------|-------|-------------|---------|63| 1 | ≥38°C | None | None |64| 2 | ≥38°C | Responsive to fluids | Low-flow O2 |65| 3 | ≥38°C | One vasopressor | High-flow O2 |66| 4 | ≥38°C | Multiple vasopressors | Ventilation |6768## Workflow69701. **Input**: Cytokine levels, vital signs, laboratory values, treatment history.71722. **Risk Assessment**: Baseline CRS risk stratification pre-therapy.73743. **Monitoring**: Real-time cytokine tracking with trend analysis.75764. **Grading**: Automated CRS grade assignment per ASTCT criteria.77785. **Differential**: Rule out mimics (infection, HLH, ICANS).79806. **Treatment**: Generate management recommendations.81827. **Output**: CRS risk score, grade, differential diagnosis, treatment plan.8384## Example Usage8586**User**: "Monitor this CAR-T patient's cytokine levels and predict CRS severity."8788**Agent Action**:89```bash90python3 Skills/Immunology_Vaccines/Cytokine_Storm_Analysis_Agent/crs_analyzer.py \91 --patient_data demographics.json \92 --cytokines cytokine_panel.csv \93 --vitals vital_signs.csv \94 --labs laboratory_values.csv \95 --cart_product tisagenlecleucel \96 --day_post_infusion 5 \97 --model crs_predictor_v3 \98 --output crs_report.json99```100101## AI/ML Models102103**CRS Risk Prediction**:104- Features: tumor burden (LDH), lymphodepletion intensity, CAR-T dose, disease type105- Model: Gradient boosting with SHAP interpretability106- Performance: AUC 0.82-0.88 for severe CRS107108**Severity Trajectory**:109- Time-series modeling of cytokine dynamics110- LSTM networks for temporal patterns111- Early warning 24-48 hours before clinical deterioration112113**Treatment Response**:114- Tocilizumab response prediction115- Corticosteroid escalation timing116- ICU admission risk117118## Differential Diagnosis Decision Tree119120```121Fever + Elevated Cytokines122 |123 CAR-T context?124 / \125 Yes No126 | |127Hypotension? Infection workup128 | |129 CRS Sepsis vs viral130 |131Neuro symptoms?132 |133 ICANS vs CRS134 |135Ferritin >10,000?136 |137 HLH/MAS evaluation138```139140## Clinical Decision Support141142**Tocilizumab Indication**:143- Grade 2+ CRS144- Rapidly rising cytokines145- High-risk baseline features146147**Corticosteroid Indication**:148- Tocilizumab-refractory CRS149- ICANS any grade150- Grade 3+ CRS151152## Prerequisites153154* Python 3.10+155* scikit-learn, XGBoost for ML156* Time-series analysis libraries157* FHIR client for EHR integration158159## Related Skills160161* CART_Design_Optimizer_Agent - For CAR-T design162* TCell_Exhaustion_Analysis_Agent - For T-cell function163* Clinical_NLP - For extracting symptoms from notes164165## Special Populations1661671. **Pediatric**: Different baseline cytokine ranges1682. **Post-COVID**: Altered inflammatory responses1693. **Bridging Therapy**: Impact on CRS risk1704. **Concurrent Infection**: Confounding cytokine elevation171172## Author173174AI Group - Biomedical AI Platform175176177<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->